Development, HR and Radiology - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Development

Radiology

Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021

The Pharma Data

MARCH 17, 2021

percent compared to ET alone – a statistically significant improvement in invasive disease-free survival for HR+, HER2- high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009). In adjuvant breast cancer trials, this includes the length of time before any cancer comes back, a new cancer develops or death.

HR Trials In-Vitro Manufacturing

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19

The Pharma Data

OCTOBER 22, 2020

The speed and rigor with which Veklury has been developed and approved in the U.S. vs. 15.2%, HR 0.73; 95% CI, 0.52 94% on room air, and radiological evidence of pneumonia. Moderate COVID-19 was defined as confirmed SARS-CoV-2 infection, SpO2 >94% and radiological evidence of pneumonia. About Veklury.

FDA Approval

FDA Approval Trials Clinical Trials Clinical Trials

Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19

Stay Connected